[The effect of growth hormone replacement therapy on markers of bone formation and bone mineral density in elderly men].

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

Decline in growth hormone (GH) secretion and serum levels of insulin-like growth factor-1 (IGF-1) during ageing may be a causal factor in the development of osteopenia.

Who Took Part

The abstract describes 18 men taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, men only.

18 healthy men aged 60.2 +/- 2.4 (avg +/- SEM) with mean body weight 78.6 +/- 4.6 kg and body mass index (BMI) 26.5 +/- 1.4 kg/m2.

Nine healthy men aged 27.5 +/- 1.3 were recruited as a control subjects.

How the Study Was Run

Their body weight was 76.3 +/- 2.2 kg and BMI 21.3 +/- 0.6 kg/m2.

Lumbar spine and femoral neck bone mineral density (BMD) were measured by dual-energy X-ray absorptiometry.

What Was Measured

PubMed files the paper under topics including Aging, Alkaline Phosphatase, Bone Density, Bone Diseases, Metabolic, Femur Neck, Growth Substances and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Polskie Archiwum Medycyny Wewnetrznej), a journal based in Poland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.